HomeNZYMB • SWX
add
Novozymes A/S
Previous close
CHF 44.68
Year range
CHF 44.68 - CHF 44.68
Market cap
158.65B DKK
P/E ratio
-
Dividend yield
-
Primary exchange
CPH
Market news
Financials
Income Statement
Revenue
Net income
| (DKK) | Dec 2023info | Y/Y change |
|---|---|---|
Revenue | 4.60B | 1.63% |
Operating expense | 1.42B | -7.08% |
Net income | 698.00M | -20.95% |
Net profit margin | 15.16 | -22.26% |
Earnings per share | 3.06 | 536.62% |
EBITDA | 1.21B | 17.08% |
Effective tax rate | 24.70% | — |
Balance Sheet
Total assets
Total liabilities
| (DKK) | Dec 2023info | Y/Y change |
|---|---|---|
Cash and short-term investments | 1.12B | 7.20% |
Total assets | 28.39B | 1.46% |
Total liabilities | 14.04B | 2.07% |
Total equity | 14.35B | — |
Shares outstanding | 464.62M | — |
Price to book | 0.89 | — |
Return on assets | 9.38% | — |
Return on capital | 12.09% | — |
Cash Flow
Net change in cash
| (DKK) | Dec 2023info | Y/Y change |
|---|---|---|
Net income | 698.00M | -20.95% |
Cash from operations | 1.12B | 92.12% |
Cash from investing | -603.00M | 32.85% |
Cash from financing | -555.00M | -2,513.04% |
Net change in cash | -59.00M | 82.44% |
Free cash flow | 718.50M | 51.90% |
About
Novozymes A/S was a global biotechnology company headquartered in Bagsværd, outside of Copenhagen, Denmark. The company's focus was the research, development and production of industrial enzymes, microorganisms, and biopharmaceutical ingredients. The company merged with Chr. Hansen to form Novonesis in January 2024.
Prior to the merger, the company had operations around the world, including in China, India, Brazil, Argentina, United Kingdom, the United States, and Canada. Class B shares of its stock were listed on the NASDAQ OMX Nordic exchange.
On 12 December 2023, it was announced that Nozozymes and Danish bioscience company Chr. Hansen had obtained regulatory approval for a merger, and on the following day, the name of the combined company was revealed as Novonesis. Wikipedia
CEO
Founded
2000
Website
Employees
6,577
